Summary
Simvastatin is a potent lipid-lowering agent that has proven highly effective in the treatment of primary hypercholesterolaemia. This report extends the data on controlled clinical trials, involving 2423 patients receiving simvastatin. The mean duration of treatment was 1.5 years, and some patients were followed up for a period of up to 4.3 years. This cohort had a mean age of 50 years, with males comprising 61% of the population. Because of the severity of lipid abnormalities treated in this population, simvastatin was titrated to the maximum daily dose of 40mg each evening in over half the population. An evaluation of long term efficacy indicates that improvements in the lipid/lipoprotein profile observed initially in patients were maintained over 3 years of treatment with chronic administration. The improvements in plasma levels included reductions in total and low-density lipoprotein cholesterol, decreases in triglyceride and increases in high-density lipoprotein cholesterol plasma levels. The profile of adverse events remained unchanged since the initial controlled clinical studies, with no reports of new or unexpected adverse effects. The most commonly reported drug-related clinical adverse experiences were gastrointestinal in nature, including constipation (in 2.5% of the patient population), abdominal pain (2.5%), flatulence (2.0%) and nausea (1.2%). Persistent elevations in levels of serum transaminases > 3 times the upper limit of normal were observed in 1.2% of the population, but rarely required discontinuation of therapy. Elevations in levels of creatine Phosphokinase (CPK) > 10 times the upper limit of normal were infrequent (0.7%), and reports of myopathy were rare (0.08%). Elderly patients (aged ⩾ 65 years) had a clinical and laboratory tolerability profile comparable to the nonelderly population. The long term clinical experience with simvastatin confirms its efficacy and tolerability profile for the treatment of hypercholesterolaemia.
Similar content being viewed by others
References
Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Journal of Lipid Research 30: 567–582, 1990
Barth JD, Kruisbrink OA, Van Eijk AL. Sleep duration and sleep patterns during simvastatin therapy (Abstract). Tenth International Symposium on Drugs Affecting Lipid Metabolism, Houston, Texas, No. 514, 1989
Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long term safety and efficacy profile of simvastatin. American Journal of Cardiology 68: 1127–1131, 1991
Bradford RH, Shear CI, Chremos AN, DuJovne C, Downtown M, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Archives of Internal Medicine 151: 43–49, 1991
Eckernas SA, Roos BE, Kvidal P, Eriksson L-O, Block GA, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolemia. British Journal of Clinical Pharmacology, in press, 1993
Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. Journal of the American Medical Association 262: 1479–1514, 1989
Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. American Journal of Medicine 87: 28S–38S, 1989
Mol MJ, Erkelens DW, Gevers LJA, Schouten JA, Stalenhoef AFH. The effect of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 2: 936–939, 1986
Mol MJ, Erkelens DW, Gevers LJA, Schouten JA, Stalenhoef AFH. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis 69: 131–137, 1988
Molgaard J, von Schenk H, Olsson AG. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolemia. European Heart Journal 9: 541–551, 1988
Newman TJ, Kassler-Taub KB, Gelarden RT, Korzin EG, De Vault AR, et al. Safety of pravastatin in long-term clinical trials conducted in the United States. Journal of Drug Development 3: 275–280, 1990
Pan H, US Food and Drug Administration Advisory Committee Proceedings on Pravastatin, Oct. 23, 1990. Miller Reporting Co. Inc., 507 C St NE, Washington, DC, 20002 p. 121
Pietro DA, Alexander S, Mantell G, Staggers JE, Cook TJ. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Group II). American Journal of Cardiology 63: 682–686, 1989
Pietro DA, Mantell G. Simvastatin: a new HMG-CoA reductase inhibitor. Cardiovascular Drug Reviews 8: 220–228, 1990
Stein EA, Kreisberg R, Miller V, Mantell G, Washington L, et al. Effects of simvastatin and cholestyramine in familial and non-familial hypercholesterolemia. Archives of Internal Medicine 150: 341–345, 1990
Tikkanen MJ, Bocanegra TS, Walker JF, Cook T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol: a multicenter study. American Journal of Medicine 87 (Suppl. 4A): 46–53, 1989
Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. American Journal of Cardiology 62: 28J–34J, 1988a
Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (corresp.). New England Journal of Medicine 318: 47–48, 1988b
Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. American Journal of Cardiology 65: 23F–26F, 1990
Walker JF. Simvastatin: the clinical profile. American Journal of Medicine 87: 4A–44S, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boccuzzi, S.J., Keegan, M.E., Hirsch, L.J. et al. Long Term Experience with Simvastatin. Drug Invest. 5, 135–140 (1993). https://doi.org/10.1007/BF03259587
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259587